共 10 条
[1]
Elevated mitogen-activated protein kinaseactivity in estrogen-nonresponsive human breast cancer cels. Coutts AS,Murphy LC. Cancer Research . l998
[2]
ERK phosphorylation islinked to VEGFR2expression and Ets-2phosphorylation in breastcancer and is associated with tamoxifen treatment resistance andsmall tumours with good prognosis. Svensson S,Jirstrom K,Ryden L,et al. Oncegene . 2005
[3]
Beyond single pathwayinhibition:MEK inhibitors as a platform for the development ofpharmacological combinations with synergistic anti-leukemic effects. Milella M,Precupanu CM,Gregorj C,et al. Current Pharmaceutical Design . 2005
[4]
Mitogenic conversion oftransforming growth factor-betal efect by oncogenic Ha-Ras-inducedactivation of the mitogen-activaled protein kinase signaling pathwayin human prostate cancer. Park BJ,,Park JI,Byun DS,et al. Cancer Research . 2000
[5]
Antiatherogenic effects ofadjuvant antiestrogens:a randomized trial comparing the effects oftamoxifen and to remifene on plasma lipid levels inpostmenopausalwomen with node-positive breast cancer. Saarto T,Blomqvist C,Ehnholm C,et al. Journal of Clinical Oncology . 1996
[6]
Temporal and quantitative regu lation of mitogen-activated protein kinase (MAPK)modulates cell motility and invasion. Krueger JS,Keshamouni VG,Atanaskova N et al. Oncegene . 2001
[7]
Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. JinW,Wu L,Liang K,et al. British Journal of Cancer . 2003
[8]
Cross-talk between signalling pathways and the multidrug resistant protein MDR-1. D ing S,Chamberlain M,Mclaren A,et al. British Journal of Cancer . 2001
[9]
Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. Zhuang L,,Lee CS,,Scolyer RA, et al. Journal of Clinical Pathology . 2005
[10]
Major difference in thehepatocarcinogenicity and DNA adduct forming ability betweentoremifene and tamoxifen in female Crl:CD(BR)rats. Hard GC,Iatropoulos MJ,Jordan K,et al. Cancer Research . 1993